Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

Published:2015-07-06 Issue:10 Volume:50 Page:1279-1285
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Hahn M,Böttcher S,Dietrich S,Hegenbart U,Rieger M,Stadtherr P,Bondong A,Schulz R,Ritgen M,Schmitt T,Tran T H,Görner M,Herth I,Luft T,Schönland S,Witzens-Harig M,Zenz T,Kneba M,Ho A D,Dreger P

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2015150.pdf

Reference35 articles.

1. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.

2. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390–3397.

3. Seymour JF, avids MS, Pagel JM, Kahl BS, Wierda WG, Puyyada S et al. ABT-199 (GDC-0199) in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: high complete response rate and durable disease control. Proceedings of ASCO; May 30–June 3 2014; Chicago, IL, USA.

4. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.

5. Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Holding the therapy in CLLp53: mechanisms to achieve durable responses;Anti-Cancer Drugs;2024-08-09

2. The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review;Frontiers in Oncology;2023-01-18

3. Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation;International Journal of Molecular Sciences;2022-02-20

4. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells;Blood Reviews;2022-01

5. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies;Journal of Clinical Oncology;2021-02-10